Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02

Recurrent glioblastoma (GBM) has a very low six-month progression free survival (PFS) with currently available treatments. Combination chemotherapy to target multiple cell signaling pathways is currently being investigated in order to improve prognosis for recurrent disease. The purpose of this phas...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Neurooncol
Hoofdauteurs: Nghiemphu, Phioanh Leia, Ebiana, Victoria Asuquo, Wen, Patrick, Gilbert, Mark, Abrey, Lauren E, Lieberman, F, DeAngelis, Lisa M, Robins, H Ian, Yung, WK Alfred, Chang, Susan, Drappatz, Jan, Mehta, Minesh P, Levin, Victor A, Aldape, Kenneth, Dancey, Janet E, Wright, JJ, Prados, Michael, Kuhn, John, Cloughesy, Timothy F.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2017
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5756101/
https://ncbi.nlm.nih.gov/pubmed/28988377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-017-2624-4
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items